LFMD 10-Q report for 2025-09-30
LifeMD filed its Form 10-Q for the quarter ended September 30, 2025. The filing includes condensed consolidated financial statements, MD&A items, a disclosed material weakness in internal control over financial reporting, and capital‑structure details (common stock LFMD and 8.875% Series A preferred LFMDP).
Linked assets
LFMD — LifeMD, Inc. (Nasdaq: LFMD). The 10‑Q covers the quarter ended September 30, 2025 and discloses quarterly results, balance sheet, cash flows and capital‑structure information.
LifeMD, Inc. (LFMD) Form 10‑Q for quarter ended September 30, 2025 — unaudited condensed financial statements and disclosures.
LifeMD filed its Form 10‑Q for the quarter ended September 30, 2025. Key disclosed items from the filing: total assets $65,983,378 and cash $23,785,771 as of September 30, 2025; total liabilities $62,615,226; LifeMD stockholders’ equity $1,314,334 and total equity including non-controlling interest $3,368,152. Nine‑month revenue was $186,975,039 and net loss for the nine months was $(4,323,177). The company disclosed an additional material weakness in internal control over financial reporting (also present as of prior interim dates). The filing contains operating and cash flow detail (net cash provided by operating activities $11,560,698 for the nine months) and capital‑structure notes (common stock LFMD; 8.875% Series A preferred LFMDP). This information confirms the filing, summarizes reported results and highlights the material weakness — useful for diligence and capital‑structure/dilution considerations but not a specific near‑term trading catalyst on its own.
Source proof
Source proof: Strong source proof | 1 directional asset | 1 supporting author | headline-like title review
This play is based on LifeMD, Inc.’s Form 10‑Q for the quarterly period ended September 30, 2025. The filing contains unaudited condensed consolidated balance sheets, statements of operations, statements of cash flows, notes and disclosures (including an identified additional material weakness in internal controls).
This excerpt is only the cover page/header of Sleep Number’s Form 10-Q for the quarter ended April 4, 2026. It contains filing metadata (issuer, ticker, exchange, address) but no financial statements, MD&A, guidance, risks, or operational commentary. As a result, it is not directly actionable for trading beyond confirming the filing exists.
The provided excerpt is only the cover/filing header of SoundHound AI, Inc.’s 10‑Q for the quarter ended 2026‑03‑31. It contains listing/security identifiers (SOUN, SOUNW) but no financial statements, MD&A, guidance, risk updates, liquidity details, or material events. As a result, there is insufficient information to form high-confidence, actionable bullish/bearish theses beyond generic “company filed its 10‑Q” metadata.
The provided excerpt is only the boilerplate cover/filing-status section of Teucrium Commodity Trust’s Form 10‑Q for period ended 2026‑03‑31, with no portfolio holdings, performance, risk, or material updates included. As-is, it contains no actionable investment information beyond confirming the existence of the filing and the issuer/ticker identity (WEAT).
This excerpt is only the cover page of Archer Aviation’s Form 10‑Q for the quarter ended 2026‑03‑31 (issuer identity, exchange listing, and securities outstanding). It contains no operating/financial results, guidance, liquidity details, backlog, or risk-factor updates—so it is minimally actionable for trading beyond basic security identifiers and a generic dilution/optionality consideration from warrants.
This excerpt is essentially the cover page of CleanSpark, Inc.’s Form 10-Q for the quarter ended March 31, 2026. It contains identifiers (CIK/file no.), listing venue, and security descriptions (common stock and redeemable warrants with specific exercise terms), but no operating/financial results, guidance, risks, or MD&A detail. Actionability is therefore limited to capital-structure/dilution considerations around the listed warrant.
This excerpt of AST SpaceMobile’s 10‑Q is largely SEC cover-page/boilerplate (registrant info, exchange listing, filing compliance) and contains no financial results, guidance, liquidity, risk-factor updates, or operating metrics. As provided, it does not create a clear tradable catalyst beyond confirming continued reporting/listing status.
This excerpt only includes the cover page of Super Micro Computer, Inc.’s Form 10‑Q for the quarter ended March 31, 2026. It confirms the filing, issuer identity, listing (Nasdaq), and ticker (SMCI), but contains no financial results, guidance, risks, or MD&A content to support a directional investment view.
The provided text is only the cover/header portion of AbCellera Biologics Inc.’s Form 10‑Q for the quarter ended March 31, 2026 (identifying info, exchange listing, filing status). It contains no financial statements, guidance, risk updates, material events, MD&A, cash runway, pipeline/program updates, or disclosures that would support a differentiated trading view.
Supporting authors
Single source: the LifeMD Form 10‑Q filing (quarter ended September 30, 2025).
Unlock full thesis monitoring
Action: review the Form 10‑Q for details on revenue composition, cash runway, debt extinguishment effects and the noted material weakness before taking or adjusting positions.